Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 56.9 -1.0 - View Chart
P/BV x 13.7 0.1 19,128.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
VENUS REMEDIES
Mar-18
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs8,834126 7,016.8%   
Low Rs5,45861 8,932.1%   
Sales per share (Unadj.) Rs1,731.1301.8 573.6%  
Earnings per share (Unadj.) Rs211.9-24.9 -852.1%  
Cash flow per share (Unadj.) Rs219.92.5 8,641.2%  
Dividends per share (Unadj.) Rs65.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs945.2293.3 322.3%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.10.3 1,332.4%   
Avg P/E ratio x33.7-3.8 -896.9%  
P/CF ratio (eoy) x32.536.7 88.4%  
Price / Book Value ratio x7.60.3 2,371.3%  
Dividend payout %30.70-   
Avg Mkt Cap Rs m151,8481,154 13,160.8%   
No. of employees `0003.50.9 376.8%   
Total wages/salary Rs m4,356393 1,108.1%   
Avg. sales/employee Rs Th10,555.54,026.1 262.2%   
Avg. wages/employee Rs Th1,249.9425.0 294.1%   
Avg. net profit/employee Rs Th1,292.2-331.8 -389.5%   
INCOME DATA
Net Sales Rs m36,7863,724 987.8%  
Other income Rs m1,13323 5,035.1%   
Total revenues Rs m37,9193,747 1,012.1%   
Gross profit Rs m6,047395 1,531.7%  
Depreciation Rs m169338 50.0%   
Interest Rs m23354 6.4%   
Profit before tax Rs m6,989-275 -2,538.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,48532 7,864.6%   
Profit after tax Rs m4,503-307 -1,467.4%  
Gross profit margin %16.410.6 155.1%  
Effective tax rate %35.6-11.5 -309.8%   
Net profit margin %12.2-8.2 -148.5%  
BALANCE SHEET DATA
Current assets Rs m27,6102,638 1,046.7%   
Current liabilities Rs m8,5692,305 371.8%   
Net working cap to sales %51.88.9 578.8%  
Current ratio x3.21.1 281.5%  
Inventory Days Days60135 44.5%  
Debtors Days Days2746 59.1%  
Net fixed assets Rs m1,0574,871 21.7%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m19,8733,496 568.5%   
Net worth Rs m20,0863,619 555.0%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m29,4097,509 391.7%  
Interest coverage x311.60.2 139,746.7%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.5 252.2%   
Return on assets %15.40.6 2,437.7%  
Return on equity %22.4-8.5 -264.4%  
Return on capital %34.91.6 2,206.3%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m4,918517 952.3%   
Net fx Rs m-4,549-517 880.8%   
CASH FLOW
From Operations Rs m4,991514 970.3%  
From Investments Rs m-2,570-123 2,087.7%  
From Financial Activity Rs m-1,428-387 368.9%  
Net Cashflow Rs m9934 23,650.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)

Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 13, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - FULFORD INDIA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS